about
sameAs
Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduriaMechanisms of glutamate transportNa+ interactions with the neutral amino acid transporter ASCT1.Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth.The domain interface of the human glutamate transporter EAAT1 mediates chloride permeationPosition of the third Na+ site in the aspartate transporter GltPh and the human glutamate transporter, EAAT1.Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.Transport rates of a glutamate transporter homologue are influenced by the lipid bilayer.Allosteric modulation of neurotransmitter transporters at excitatory synapses.A channel in a transporter.Identification of a 3rd Na+ Binding Site of the Glycine Transporter, GlyT2.Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.Oleoyl-L-carnitine inhibits glycine transport by GlyT2Tuning the ion selectivity of glutamate transporter-associated uncoupled conductancesFunctional characterization of a Na+-dependent aspartate transporter from Pyrococcus horikoshii.Lipid inhibitors of high affinity glycine transporters: identification of a novel class of analgesics.Glycine transport inhibitors for the treatment of pain.The amino acid transporter, SLC1A3, is plasma membrane-localised in adipocytes and its activity is insensitive to insulin.Molecular determinants for functional differences between alanine-serine-cysteine transporter 1 and other glutamate transporter family members.Distinct conformational states mediate the transport and anion channel properties of the glutamate transporter EAAT-1.Prostaglandin E(2) inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons.The chloride permeation pathway of a glutamate transporter and its proximity to the glutamate translocation pathway.Effects of sumatriptan on rat medullary dorsal horn neurons.The role of cation binding in determining substrate selectivity of glutamate transporters.Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2.Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2.Brain transporters: From genes and genetic disorders to function and drug discovery.Glycine transporter2 inhibitors: Getting the balance right.Characterization of the Inward- and Outward-Facing Substrate Binding Sites of the Prokaryotic Aspartate Transporter, GltPh.Targeting glutamine transport to suppress melanoma cell growth.Site-directed mutagenesis in the study of membrane transporters.Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.The uncoupled chloride conductance of a bacterial glutamate transporter homologRegulation of SLC1A4 and SLC1A5 in Prostate Cancer-LetterSynthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1AElevating the alternating-access modelThe Split Personality of Glutamate Transporters: A Chloride Channel and a TransporterWater and urea permeation pathways of the human excitatory amino acid transporter EAAT1Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain
P50
Q24310676-0053FE43-0A39-45BB-BB94-50BA72CC7229Q26830761-16ACD656-6649-4ED6-997A-7FEA4379141BQ33792891-D7704CA7-8D20-47AB-98BB-CD1E0DB4AD16Q33797210-F33B3CB6-EBDB-40A6-BBA8-17F8D3807E9EQ34031064-C42C2318-08CE-4C72-9C3C-64F2D2ED4B29Q34200400-2BBDACB0-7138-461E-BD33-FC2EF3A1E99BQ35236755-4FFC1BE9-7BE0-40F7-B0A2-6AF2204BDFC5Q35352039-CC447D1F-BA86-4E7B-8D1B-1FDC0ABC4B17Q35868865-97E56985-FE1D-4E81-BDA4-572243AE51C8Q36054043-C22A8098-2288-4516-95D6-D080DDF8ECE0Q36060232-28EE95F1-47F8-4FE9-B2F7-C6FB556447B0Q36282217-70FE44D6-1C65-4AD9-AB51-E0131CE02C28Q36781047-0045E4F9-0639-4BFA-BC8D-3C3CB309B52FQ37047085-D3D7890C-3519-4534-A66F-3FBF6E062585Q37285230-D55C5355-9796-4FB4-B5F7-FE98AEDA4A7AQ38137633-39B5419C-2AE4-4FB9-9B40-7174A49B0664Q38222971-12924742-948E-4136-A0EC-503A2FE3CE88Q41791641-6BBD5F94-942B-4CD2-B41E-23C37870420DQ43219312-7024A7A3-8F58-410B-95D0-BE471F302B23Q43869538-1A1348A6-EC77-4E5F-A7A6-E7A9E95AC520Q43908344-81A1AEB3-4719-4436-BF7A-D14C5A6C9541Q44776061-D69147DD-F9E3-4286-B515-841C2A8B630EQ45029192-10A8A43E-7202-43AC-A997-50AD921510A6Q46202485-8CA8F36D-53E2-4D7B-A6BD-8DC21C0D8303Q47754240-CB905E33-37B0-4189-96E0-58C948FA3787Q47819910-B8BDEF0D-A360-410A-BCD7-1E17F13F67DFQ48334358-4DB7A303-B2EE-41DA-B54E-078D91932B41Q48594872-CCA86013-95AD-4D72-80A3-F1BF631EC406Q49061572-0DFA54D5-7999-4609-89B5-88861DA6221AQ51272452-5B5230C2-9F49-4E55-81E4-97B39D42AD6EQ54376941-AD6881DA-CBC0-4B2A-A122-AA4F9ABCD7CFQ54430998-CFAAB166-A92F-43AD-925E-58AE3139889FQ55435354-14B0B33D-74EF-4F1A-A87C-465D78AADD56Q57084779-B10F3372-F087-4CC1-8513-7535BFE99BFBQ58568421-AD6CDC5A-D280-46EB-BF37-7E4C6E1726ABQ58600404-330628A8-E733-4C29-AFEB-A0C562D1CA74Q61917206-3E8EC64F-85AC-4212-8356-4749B71A8DD6Q61917209-43FEA386-93F3-4E59-B430-560231B48A2DQ61917217-D728D94B-6CD3-45B8-ADA6-4B476180E24AQ64267066-2BDAC9A2-ECA6-4383-A695-42504E85C3D2
P50
description
Australian neuroscientist
@en
onderzoekster uit Australië
@nl
taighdeoir
@ga
հետազոտող
@hy
name
Renae M Ryan
@es
Renae M. Ryan
@en
Renae M. Ryan
@ga
Renae M. Ryan
@nl
Renae M. Ryan
@sl
Renae M. Ryan
@sq
Renae Ryan
@ast
type
label
Renae M Ryan
@es
Renae M. Ryan
@en
Renae M. Ryan
@ga
Renae M. Ryan
@nl
Renae M. Ryan
@sl
Renae M. Ryan
@sq
Renae Ryan
@ast
altLabel
Renae Ryan
@en
prefLabel
Renae M Ryan
@es
Renae M. Ryan
@en
Renae M. Ryan
@ga
Renae M. Ryan
@nl
Renae M. Ryan
@sl
Renae M. Ryan
@sq
Renae Ryan
@ast
P106
P1153
7402191715
P19
P1960
SrIv624AAAAJ
P21
P27
P31
P496
0000-0002-8680-4610
P569
1977-10-11T00:00:00Z
2000-01-01T00:00:00Z